ReviewVascular health and risk management2009
Redefining the role of thiazolidinediones in the management of type 2 diabetes.
Review in Vascular health and risk management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis.Journal of endocrinological investigation · 2016Pooled it
- Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review.Journal of neurochemistry · 2010Pooled it
- Adipokines as Cardioprotective Factors: BAT Steps Up to the Plate.Biomedicines · 2025Review
- Peroxisome proliferator-activated receptors as targets to treat metabolic diseases: Focus on the adipose tissue, liver, and pancreas.World journal of gastroenterology · 2023Review
- The Impact of Exercise on Immunity, Metabolism, and Atherosclerosis.International journal of molecular sciences · 2023Review
- Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes.Reviews in endocrine & metabolic disorders · 2021Review
- Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic mellitus: a cohort-based case-control study.BMC pulmonary medicine · 2021Article
- SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.Physiological reports · 2019Article
- Article
- PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.Future cardiology · 2017Review
- Practical combination therapy based on pathophysiology of type 2 diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2016Review
- Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.PPAR research · 2015Review
- Peroxisome proliferator-activated receptors for hypertension.World journal of cardiology · 2014Review
- Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination.Patient preference and adherence · 2014Review
- Differential sensitivities of the vascular K(ATP) channel to various PPAR activators.Biochemical pharmacology · 2013Article
- Rosiglitazone selectively inhibits K(ATP) channels by acting on the K(IR) 6 subunit.British journal of pharmacology · 2012Article
- Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline.British journal of pharmacology · 2011Article
- Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?Parkinson's disease · 2011Article
- Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2011Article
- Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.Future cardiology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a need to evaluate oral glucose-lowering agents not only for their value in achieving glycemic control but also for their impact on cardiac risk factor modification. This article reviews the evidence base for the two thiazolinediones currently available, pioglitazone and rosiglitazone. These drugs exert their effects through actions affecting metabolic control, lipid profiles, and the vascular wall. They have been shown to be as efficacious in establishing glycemic control, in both monotherapy and combination therapy regimens, as more traditional oral agents, and may be able to sustain that control in the long term. Both thiazolidinediones have demonstrated favorable effects on markers of cardiovascular disease. Evidence from the large PROactive outcomes study suggests that pioglitazone may exert protective effects in patients with type 2 diabetes and macrovascular disease. Thiazolidinediones are generally well tolerated but they can cause weight gain, induce fluid retention, and may contribute to bone loss in postmenopausal women. The place of thiazolidinediones in the management of type 2 diabetes is well established. The potential for additional benefits in reducing macrovascular risk encourages further long-term study of these agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.